Astra Drug Doesn’t Help With Tough Form of Breast Cancer (1)

June 18, 2024, 7:02 AM UTC

AstraZeneca Plc’s new medicine Truqap didn’t help patients with a hard-to-treat form of breast cancer live longer.

Scientists studied the drug in combination with a common chemotherapy in the late-stage study, the drugmaker said Tuesday. The volunteers had triple-negative breast cancer, one of the most challenging forms of the disease to treat, which had spread or couldn’t be operated.

Truqap, a potential new cancer blockbuster for Astra, recently won clearance in the US and the European Union for other types of breast cancer.

The new study’s outcome is disappointing but may help advance understanding of certain pathways, said Susan ...





Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.